进展分析与传统方法对比,以量化阿尔茨海默氏病中疾病进展的减缓
Linus Jönsson1, Milana Ivkovic2, Alireza Atri3,4
1Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, 171 64, Sweden. Linus.jonsson@ki.se.
Alzheimer's research & therapy
|February 29, 2024
概括
对阿尔茨海默病的疾病修饰治疗可能会减缓进展. 一个新的模型将短期影响转化为有意义的时间延迟,为患者和临床医生提供更好的解释.
科学领域:
- 神经科学是一个神经科学.
- 临床试验 临床试验
- 生物统计学 生物统计学
背景情况:
- 阿尔茨海默病治疗的临床意义受到争议,对长期益处的理解有限.
- 目前的证据主要集中在评级尺度的短期影响上,这些评级尺度缺乏以患者为中心的解释性.
- 预计疾病修饰治疗 (DMT) 将在长期内延迟或减缓疾病的进展.
研究的目的:
- 评估短期治疗效应转化为阿尔茨海默病可解释的时间延迟.
- 为了比较重复测量进展模型 (PMRM) 和重复测量混合模型 (MMRM) 在估计治疗效果方面的有效性.
- 用健康经济模型评估治疗引起的延迟对疾病进展和预期寿命的长期影响.
主要方法:
- 在假设的阿尔茨海默氏症临床试验中,对活性和安慰剂手臂的模拟疾病进展轨迹.
- 利用阿尔茨海默病神经成像计划 (ADNI) 数据进行安慰剂手臂模拟 (轻度认知障碍,粉样蛋白阳性).
- 使用PMRM和MMRM来估计治疗效果,PMRM以时间单位表达效果,MMRM以结果单位表达效果 (CDR-SB).
主要成果:
- 在36个月后,PMRM估计疾病进展延迟了20% (约7个月).
- 在36个月后,MMRM估计临床痴呆症评级尺度-盒子总和 (CDR-SB) 减少了25%.
- 基于PMRM估计的时间延迟的健康经济建模预计预期寿命增加10个月,而在严重疾病阶段没有延长时间.
结论:
- PMRM方法提供了一种有价值的方法,以量化治疗效果,以减缓疾病进展.
- 将效应转化为时间指标为患者,护理合作伙伴和临床医生提供了易于解释和有意义的结果.
- 这种方法增强了对阿尔茨海默氏症疾病疾病修饰治疗的理解和感知价值.
相关概念视频
Alzheimer's Disease: Overview
481
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
481
Alzheimer's Disease: Treatment
188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188
Comparing the Survival Analysis of Two or More Groups
186
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
186


